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Abstract
Background: Considerable controversy exists regarding the relation between maternal caffeine intake during
pregnancy and risk of low birth weight (birth weight <2,500 g). We aim to assess this association using a systematic
review and dose–response meta-analysis of prospective studies.
Methods: Potential articles were identified by searching MEDLINE and SCOPUS databases through 17 July 2013.
Two authors independently extracted information on study design, participant characteristics and estimates of
associations. Random-effects models were used to derive the summary relative risks (RRs) and corresponding
95% confidence intervals (CIs). Dose–response relationships were assessed using generalized least-squares trend
estimation.
Results: In our meta-analysis, we included 13 prospective studies: 9 with low birth weight as a binary outcome
variable (90,747 participants and 6,303 cases) and 6 with birth weight as a continuous outcome variable (10,015
participants; 2 studies reported both types of outcomes). Compared with the reference category with no or
very low caffeine intake, the RR (95% CI) of low birth weight was 1.13 (1.06 to 1.21; I
2 0.0%) for low intake (50 to
149 mg/day), 1.38 (1.18 to 1.62; I
2 31.9%) for moderate intake (150 to 349 mg/day), and 1.60 (1.24 to 2.08; I
2 65.8%)
for high intake (≥350 mg/day). In the dose–response analysis, each 100-mg/day increment in maternal caffeine
intake (around one cup of coffee) was associated with 13% (RR 1.13, 1.06 to 1.21) higher risk of low birth weight.
The association persisted in strata defined according to various study characteristics. Moderate (−33 g, 95% CI −63
to −4; I
2 0.3%) and high (−69 g, 95% CI −102 to −35; I
2 0.0%) caffeine intakes were also associated with a significantly
lower birth weight as compared with the reference category.
Conclusions: Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering
low birth weight infants. These findings support recommendations to restrict caffeine intake during pregnancy to
low levels.
Keywords: Coffee, Caffeine, Low birth weight, Small for gestational age, Intrauterine growth restriction,
Systematic review, Meta-analysis
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Globally, it has been estimated that 15.5% of all in-
fants are born low birth weight, defined as birth
weight less than 2,500 g [1]. Low birth weight is not
only associated with neonatal mortality and morbidity
[1,2], but also with a higher risk of chronic diseases
such as type 2 diabetes and cardiovascular diseases in
adult life [3].
Caffeine is a plant alkaloid found mainly in coffee, tea,
cola soft drinks and cocoa [4]. It is the most commonly
used psychoactive substance [5]. Upon ingestion, caffeine
is rapidly absorbed and readily passes the placental barrier
[6,7]. The main enzyme (cytochrome P450 1A2) involved
in caffeine metabolism is absent in both the placenta and
the fetus which can lead to caffeine accumulation in
fetal tissues [6,8,9]. The half-life of caffeine doubles in
t h em o t h e rd u r i n gp r e g n a n c ya st h er a t eo fc a f f e i n e
metabolism decreases from the first to third trimester
[10,11]. This delayed clearance of caffeine leads to higher
exposure to caffeine for the fetus. Exposure to caffeine can
also lead to vasoconstriction in the uteroplacental circula-
tion, which may in turn affect fetal growth and develop-
ment [12,13].
As many women consume caffeine-containing food
and beverages during pregnancy, the possible harmful
effects of caffeine intake on fetal and birth outcomes
warrant evaluation [4,14,15]. A number of studies have
examined the relationship of maternal caffeine intake
with low birth weight with mixed results [15,16]. There-
fore, we systematically reviewed the available prospective
epidemiological studies and conducted a meta-analysis
on the association of maternal caffeine intake during
pregnancy with risk of low birth weight and related out-
comes, such as small for gestational age (SGA) and intra-
uterine growth restriction (IUGR).
Methods
This meta-analysis was conducted and reported in ac-
cordance with the Meta-analysis of Observational Stud-
ies in Epidemiology (MOOSE) guideline [see Additional
file 1] [17].
Search strategy
Two investigators (L-WC and YW) searched MEDLINE
and SCOPUS databases through 17 July 2013 with no
language restriction. SCOPUS is an abstract and citation
database of peer-reviewed literature that includes all the
contents from the EMBASE database [18]. The search
was based on combinations of synonyms for caffeine
(including its chemical name, coffee and tea) and birth
weight (including low birth weight, SGA and IUGR).
The detailed search strategy is shown in Additional
file 2.
Selection criteria
Studies were included if they met the following criteria:
(1) the study reported data from an original, peer-
reviewed study (that is, not review articles or meeting
abstracts); (2) the study was a prospective cohort study
or nested case–control study; and (3) the authors re-
ported the risk estimates of low birth weight associated
with maternal caffeine intake (estimated total caffeine
intake or coffee intake as a proxy for total caffeine intake)
during pregnancy. We excluded studies that only pre-
sented crude estimates or did not consider potential con-
founding by smoking and studies conducted in unhealthy
populations (for example, type 1 diabetes or infertility).
We also excluded animal studies, case reports or case
series, cross-sectional studies, retrospective case–control
studies and other studies that assessed caffeine intake after
the occurrence of outcome.
Low birth weight was defined as birth weight less than
2,500 g and SGA was defined as birth weight less than the
10
th percentile for gestational age. IUGR is officially de-
fined as estimated fetal weight less than the 10
th percentile
for gestational age [19,20], but the definition used in the in-
cluded studies was based on birth weight (thus similar to
SGA). Birth weight difference was defined as the difference
in birth weight in the exposed (caffeine consumers) and
unexposed (non- or very light- caffeine consumers) groups.
The study selection was independently conducted by
two authors (L-WC and YW). We also considered non-
English articles with help from colleagues who are profi-
cient in these languages. The inter-rater agreement was
fairly good (Kappa statistic = 0.64; Kappa coefficients
that range from 0.61 to 0.80 indicate ‘substantial agree-
ment’ [21]). Discrepancies were resolved by discussion
with a third investigator (RMvD).
Data extraction
For included studies, information on study, participants,
measurement of exposure and outcome, effect estimates
and their standard errors (or related statistics) were ex-
tracted independently by two investigators (L-WC and
YW) using a standardized extraction form. Discrepancies
were resolved by discussion with a third investigator
(RMvD). Study quality assessment was done by consider-
ing characteristics such as study design, number of cases
and participants, method of exposure assessment and
adjustment of confounders. Sengpiel et al. defined SGA
using three methods and we abstracted the effect esti-
mates for outcome defined using Skjaerven’s method as
similar methods were used in other studies included in
our meta-analysis [9].
Statistical analysis
Multivariable-adjusted odds ratios (ORs), hazard ratios
(HRs) or relative risks (RRs) have been used in different
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in the meta-analysis because the incident rate was low
and OR and HR thus approximated RR [22]. For studies
that reported birth weight as a continuous variable, the
multivariable-adjusted birth weight differences (exposed
minus unexposed) were used. Low birth weight, SGA
and IUGR were treated as a single outcome in our pri-
mary analysis as they are closely related, but we also
conducted stratified analysis based on different outcomes.
For studies that reported results for more than one out-
come [23-25], results for low birth weight were used in
the main analysis due to simplicity and uniformity of its
definition.
Different studies used different cutoff points for the
caffeine intake categories. To combine the risk estimates
from different categories in different studies, we assigned
the median value for each category of caffeine intake.
When lower and upper boundaries were presented for
the category, we assigned the midpoint as an estimate of
the median caffeine intake. If the upper boundary of the
highest category was not provided, we assumed that the
boundary had the same amplitude as the second-highest
category [26]. If the lower boundary of the lowest cat-
egory was not provided, we assumed the lower boundary
to be zero [26]. Two European studies only reported cof-
fee consumption in cups but not total caffeine intake
[27,28] and we estimated caffeine intake based on the
commonly cited conversion method (107 mg caffeine
per cup of coffee) [29]. Several studies reported results
for more than one period of maternal caffeine exposure
(Table 1). We used the results for average caffeine intake
during the whole pregnancy period if available [6,23].
Subsequently, we used the results for the assessment
period most frequently used (first to second trimesters)
in studies with only one exposure period. Nonetheless,
we also included results from the other assessment
periods in stratified analyses where possible.
We first conducted analyses based on different levels
of caffeine consumption. We identified four levels of
caffeine consumption based on assigned median caffeine
consumption level: (1) reference category, (2) low caf-
feine consumption (50 to 149 mg/day), (3) moderate
caffeine consumption (150 to 349 mg/day) and (4) high
caffeine consumption (≥350 mg/day). The median caffeine
levels for the reference category were 0 mg/day in five
studies [24,30-33] and up to 50 mg/day in another four
studies [6,9,28,34]; three studies have higher median
caffeine levels for the reference category due to broad
categorization [25,27,35]. The median caffeine levels
for the highest category were >700 mg/day in three
studies [25,27,35] and we used the second highest cat-
egory (350 to 700 mg/day) of these studies to represent
‘high caffeine consumption’ in order to improve compar-
ability with other studies.
Effect estimates of the individual studies were com-
bined using the random-effects method as described by
DerSimonian and Laird [36], which considers both
within-study and between-study variations. The Cochran
Q test and I
2 statistic were used to evaluate statistical
heterogeneity among studies [37,38], and I
2 values of 25%,
50% and 75% correspond to low, moderate and high
degrees of heterogeneity, respectively [38].
We further conducted a dose–response analysis (for
binary outcomes) using the generalized least-squares trend
estimation (GLST) method as described by Greenland and
Longnecker [39,40], which computes the trend from the
correlated logRR estimates across caffeine consumption
categories. We performed a two-stage GLST method that
first estimates study-specific slopes before deriving an
overall average slope [40], because this method allowed us
to include effect estimates from studies that only reported
results for caffeine intake as a continuous variable. We
tested for a potential non-linear relationship between ma-
ternal caffeine intake and birth weight using a restricted
cubic spline random-effects model with three knots; the
P-value for non-linearity was obtained by testing the null
hypothesis that the spline term is equal to 0.
We conducted stratified analyses and meta-regression
analyses to assess potential sources of heterogeneity by
different study-level characteristics. We conducted sensi-
tivity analysis to assess the influence of each individual
study by omitting one study at a time and calculating
the summary RR for the remaining studies. Publication
bias was evaluated with the Egger’s regression test, Begg’s
adjusted rank correlation test and visual inspection of
funnel plot [41,42]. All tests were performed using STATA
version 11.2 (StataCorp, College Station, TX, USA), and
two-sided P-values <0.05 were considered statistically
significant.
Results
The flow diagram with details of the study selection
is shown in Figure 1. We included nine prospective
studies [6,9,23-25,27,28,30,31] on caffeine intake and
low birth weight, IUGR or SGA involving 90,747
participants and 6,303 cases (Table 1). In a secondary
analysis, six prospective studies [6,30,32-35] on caffeine
intake with birth weight difference as an outcome variable
were included [see Additional file 3]. In total, thirteen
studies were included for the quantitative review (two
studies reported both binary and continuous birth
weight outcomes [6,30]). An additional six studies that
reported birth weight difference were only included for
qualitative review because they did not report data for
more than two categories of caffeine intake [9,24,27,43-45]
[see Additional file 3]. All studies in this meta-analysis
were conducted in the United States, Canada or
Europe.
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First author,
year
Country Study
design
Number
of cases
Total
number
Age Exposure Method of exposure
assessment
Period of exposure
assessed
Outcome Adjustments
Martin,
1987 [30]
United
States
Cohort 70 3,654 <30 y: 69% Caffeine Interviewer-
administered
questionnaire
Early pregnancy Low birth weight Gestational age, ethnicity, parity, smoking
≥30 y: 31%
Olsen,
1991 [27]
Denmark Cohort 391 11,591 <30 y: 71% Coffee Self-administered
questionnaire
First to second
trimester
Low birth weight Smoking, social group, parity, alcohol
intake (did not adjust maternal age for
this outcome but did for birth weight) ≥30 y: 29%
Mills,
1993 [23]
United
States
Cohort 21 352 <30 y: 48% Caffeine Interview First, third trimesters
and over the whole
pregnancy
a
Low birth weight
a,
intrauterine growth
restriction
Maternal age, income, education,
pre-pregnancy weight, height, ethnicity,
parity, smoking and alcohol intake ≥30 y: 52%
Spinillo,
1994 [28]
Italy Nested
case–
control
347 1,041 Case
mean: 27.4 y
Coffee NA Variable, asked at
prenatal visit or
at delivery
Intrauterine growth
restriction
Smoking, maternal age, marital status,
parity, pre-pregnancy weight, BMI,
weight gain, previous low birth weight,
fetal sex, 1
st trimester hemorrhage,
hypertension, education, social class,
alcohol intake
Control
mean: 29.3 y
Grosso,
2001 [31]
United
States
Cohort 189 2,714 <30 y: 38% Caffeine Interviewer-
administered
questionnaire
Before 16 weeks
gestations
Intrauterine growth
restriction
Smoking, height, antenatal weight gain,
preeclampsia during index pregnancy,
parity and bleeding during the
third trimester.
≥30 y: 62%
Bracken,
2003 [24]
United
States
Cohort 108 2,291 <30 y: 47% Caffeine Interview First trimester
a &
third trimester
b
Low birth weight
a,
intrauterine growth
restriction
Maternal age, parity, number of prior
pregnancies, marital status, ethnicity,
education, height, smoking during the
third trimester and weight
≥30 y: 53%
CARE study
group,
2008 [6]
United
Kingdom
Cohort 343 2,635 Mean 30.0 y Caffeine Interviewer-
administered
questionnaire
(validated)
First, second, third
trimesters and over
the whole pregnancy
a
Intrauterine growth
restriction
Maternal age, weight, height, ethnicity,
parity, neonatal gestational age at delivery
and sex, smoking and alcohol intake
Bakker,
2010 [25]
The
Netherlands
Cohort 331 7,346 Mean 29.7 y Caffeine Self-administered
questionnaire (postal)
Third trimester Low birth weight
a,
Small for gestational
age
Gestational age at visit, maternal age,
education, ethnicity, parity, smoking,
alcohol intake, height, BMI at intake,
nutritional intake, folic acid supplement
use, maternal pregnancy complications
and fetal sex
Sengpiel,
2013 [9]
Norway Cohort 4,503 59,123 <30 y: 46% Caffeine Self-administered FFQ
(validated)
First to second
trimester
Small for gestational
age
Maternal age, pre-pregnancy BMI, parity,
history of preterm delivery, fetal sex,
nausea during second trimester, smoking,
passive smoking, nicotine intake from
other sources, alcohol intake, energy
intake, maternal education, marital status
and household income
≥30 y: 54%
adata used for the main analysis;
bdata not used because they were collected postnatally (after the occurrence of outcome). BMI, body mass index; FFQ, food frequency questionnaire; NA, not available; y, year.
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4Figure 2 shows the RRs for the association between
maternal caffeine intake and low birth weight (including
IUGR and SGA). The summary RR was 1.13 (95% CI
1.06 to 1.21) for low caffeine intake (50 to 149 mg/day),
1.38 (95% CI 1.18 to 1.62) for moderate caffeine in-
take (150 to 349 mg/day) and 1.60 (95% CI 1.24 to
2.08) for high caffeine intake (≥350 mg/day), as com-
pared with the reference category with no or very low
caffeine intake. The heterogeneity in study results was
low to moderate: I
2=0.0% for low caffeine intake, 31.9%
for moderate caffeine intake and 65.8% for high caffeine
intake.
The dose–response relationship between maternal caf-
feine intake and low birth weight is shown in Figure 3.
Because there was no evidence of departure from linearity
(P= 0.89), we assumed a linear relationship. The summary
RR was 1.13 (95% CI 1.06 to 1.21; Table 2) per 100-mg/day
(equivalent to around one cup of coffee) and 1.45 (95% CI
1.20 to 1.76) per 300-mg/day increment of maternal
caffeine intake. The overall heterogeneity was higher
(I
2 82.4%) than for the categorical comparisons. How-
ever, the summary RRs did not substantially differ by
various study characteristics including age of the mothers,
region, year of publication, size of the study population,
exposure assessment (total caffeine intake versus only cof-
fee), questionnaire administration for exposure assessment
(self-administered or interviewer-administered), assessed
period of exposure during pregnancy, outcome definition
(low birth weight, IUGR or SGA) and adjustment for
smoking (a few or multiple categories) (Table 2). In a
sensitivity analysis, the summary RRs ranged from 1.11
(95% CI 1.04 to 1.17) to 1.16 (95% CI 1.08 to 1.24) per
100-mg/day increment in maternal caffeine intake when we
omitted one study at a time.
Figure 1 Flow chart of study selection.
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feine intake and birth weight as a continuous outcome
variable. As compared with the reference group with no
or very low caffeine intake, birth weight was 9 g lower in
the low caffeine intake group (95% CI −16 to 35), 33 g
lower in the moderate caffeine intake group (95% CI 4
to 63), and 69 g lower in the high caffeine intake group
(95% CI 35 to 102) (Figure 4). The heterogeneity in
study results was low (I
2=0.0% for low and high caffeine
intakes, and 0.3% for moderate caffeine intake). As the
results in the study by Brooke et al. were reported separ-
ately for smokers and non-smokers, the potential impact
of including two data points from the same study was
assessed by excluding either of the data points, but the
heterogeneity remained low (I
2=0.0% for low and high
caffeine intakes, and around 13% for moderate caffeine
intake). For studies that were included for qualitative
review only [see Additional file 3] [9,24,27,43-45], higher
maternal caffeine intake was consistently associated with
lower birth weight and this association was significant in
five out of six studies [9,24,27,43,45].
There was no suggestion of publication bias based on
Egger’s test (P =0.22), Begg’s test (P =0.60) or the funnel
plot [see Additional file 4].
Discussion
The findings from this meta-analysis of prospective
studies suggest that maternal caffeine intake is associ-
ated with a higher risk of delivering an infant with low
birth weight. Low caffeine intake (50 to 149 mg/day) was
associated with a 13%, moderate caffeine intake (150
to 349 mg/day) with a 38%, and high caffeine intake
(≥350 mg/day) with a 60% higher risk of low birth
weight as compared with very low or no caffeine intake.
These results suggest a graded relationship between
caffeine intake and low birth weight. In a dose–response
analysis, each 100-mg/day increment in maternal caffeine
intake (about one cup of coffee) was associated with a
13% higher risk for low birth weight. The association per-
sisted across strata defined by various study and partici-
pant characteristics.
Most previous reviews on maternal caffeine intake and
low birth weight only qualitatively summarized the avail-
able evidence [15,16,46]. The most recent quantitative
reviews only considered studies published up to year
1996 [47,48]. The meta-analysis conducted by Fernandes
et al. suggested that pregnant women consuming more
than 150 mg caffeine per day had a significantly higher
risk of low birth weight compared with those with a
lower caffeine intake [48]. This meta-analysis included
only five studies and pooled crude effect estimates; con-
founding by factors such as smoking and maternal age
is, thus, a concern. Similarly, in the other older meta-
analysis, Santos et al. reported an association between
Figure 2 Relative risks of low birth weight/IUGR/SGA according
to maternal caffeine intake. Low caffeine intake: 50 to 149 mg/day;
moderate caffeine intake: 150 to 349 mg/day; high caffeine
intake: ≥350 mg/day. Black dots indicate study-specific effect
estimates, sizes of the grey squares correspond to the weights
of the studies, horizontal lines indicate 95% CIs, and diamonds
indicate the summary estimates with their corresponding 95% CIs. CI,
confidence interval; IUGR, intrauterine growth restriction; SGA, small for
gestational age.
Figure 3 Dose–response relationship between maternal
caffeine intake and low birth weight/IUGR/SGA (n=7). Adjusted
relative risks (RRs) and 95% CIs (dashed lines) are reported. Caffeine
intake was modeled with a linear trend (P-value for non-linearity=0.89)
in a random-effects model. The vertical axis is on a log scale. The open
circles represent the effect estimates from each study (the number of
circles for a study depends on the number of caffeine intake categories
in the study) and the size of the circles is proportional to the precision
of the estimates. Mills et al.’s [23] and Sengpiel et al.’s[ 9 ]s t u d i e s
were not included in this graph as they did not provide sufficient
results for categories of caffeine intake. CI, confidence interval; IUGR,
intrauterine growth restriction; LBW, low birth weight; SGA, small for
gestational age.
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Characteristics Number of studies Summary RR (95% CI) P-for-difference P-for-heterogeneity I
2 (95% CI)
All studies 9 1.13 (1.06 to 1.21) <0.01 82.4 (65.4 to 89.1)
Region
United States 4 1.20 (0.95 to 1.52) Ref. 0.01 75.5 (32.3 to 91.1)
Europe 5 1.12 (1.05 to 1.19) 0.60 <0.01 87.2 (69.2 to 92.7)
Year of publication
In or after 2000 5 1.10 (1.04 to1.16) 0.29
a 0.07 53.9 (0.0 to 81.0)
Before 2000 4 1.27 (1.02 to 1.58) <0.01 89.1 (74.8 to 95.3)
Study population
≥2,500 6 1.11 (1.04 to1.18) Ref. <0.01 86.0 (68.9 to 91.8)
<2,500 3 1.28 (1.14 to 1.44) 0.25 0.45 0.0 (0.0 to 89.6)
Study design
Cohort 8 1.11 (1.04 to 1.18) Ref. <0.01 81.0 (59.1 to 88.7)
Nested case–control 1 1.33 (1.16 to 1.52) 0.21 - -
Exposure
Caffeine 7 1.13 (1.06 to 1.21) Ref. 0.01 67.4 (0.0 to 83.4)
Coffee 2 1.16 (0.91 to 1.48) 0.93 <0.01 91.9 (NA)
Outcome
b
LBW 5 1.12 (1.02 to 1.23) Ref. <0.01 75.8 (40.6 to 90.1)
IUGR 5 1.12 (1.00 to 1.25) 0.78 0.04 59.5 (0.0 to 82.8)
SGA 2 1.13 (1.07 to 1.18) 0.85 0.14 53.9 (NA)
Age
c
<30 years 4 1.17 (1.05 to 1.31) Ref. <0.01 88.6 (73.4 to 95.1)
≥30 years 5 1.13 (1.08 to 1.19) 0.54 0.32 15.1 (0.0 to 69.2)
Method of exposure assessment
Interviewer-based 5 1.17 (1.01 to 1.36) Ref. 0.01 68.2 (17.9 to 87.7)
Self-administered 3 1.08 (1.01 to 1.16) 0.42 <0.01 90.7 (70.5 to 95.2)
NA 1 1.33 (1.16 to 1.52) 0.38 - -
Exposure period assessed
b
First trimester 3 1.17 (0.90 to 1.53) Ref. <0.01 83.0 (48.0 to 94.4)
First to second trimesters 2 1.09 (0.99 to 1.21) 0.62 <0.01 95.3 (NA)
Whole pregnancy 2 1.13 (1.04 to 1.24) 0.99 0.40 0.0 (NA)
Third trimester 2 1.06 (1.00 to 1.12) 0.64 0.63 0.0 (NA)
NA 1 1.33 (1.16 to 1.52) 0.51 - -
Adjustment for smoking
d
Fine 7 1.12 (1.04 to 1.20) Ref. <0.01 82.0 (59.1 to 89.6)
Crude 2 1.24 (0.89 to 1.72) 0.52 <0.01 91.7 (NA)
Median population caffeine intake
<200 mg/d 5 1.15 (1.05 to 1.26) 0.32
a 0.02 66.7 (0.0 to 85.1)
≥200 mg/d 3 1.10 (1.01 to 1.21) <0.01 83.9 (51.8 to 94.7)
NA 1 1.40 (0.84 to 2.32) - -
aP-value was obtained by modeling year of publication and median of assigned doses as continuous variables;
btotal number of study is more than 9 because
some studies reported additional (usable) results for a different outcome or exposure period;
cmean age <30 years or ≥30 years. If mean age is not available,
classification was based on whether the majority of the population (>50%) is <30 years or ≥30 years;
dfine adjustment for smoking refers to studies that adjusted
for amount of smoking or studies that adjusted for smoking using a biomarker; crude adjustment refers to studies that did not adjust for amount of smoking. I
2,
I-squared; IUGR, intrauterine growth restriction; LBW, low birth weight; NA, not available; Ref., reference. RR, relative risk; SGA, small for gestational age.
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offspring’s birth weight and higher risks of having low
birth weight and IUGR newborns [47]. However, the
study only compared the extreme groups and the influ-
ence of moderate and low caffeine consumption during
pregnancy remained unclear. Moreover, this meta-analysis
combined estimates from cohort studies and case–control
studies, which may be more prone to selection and recall
biases.
To date, only one randomized controlled trial has
studied the effect of a reduction in caffeine intake during
pregnancy on birth weight [49]. This Danish study ran-
domized 1,207 pregnant women into two groups that
received either caffeinated instant coffee or decaffeinated
instant coffee starting at about 20 weeks of gestation and,
thus, only evaluated the effect of caffeine reduction in the
second half of pregnancy. The estimated mean caffeine
intake of the caffeinated coffee group was 182 mg/day
higher than that of the decaffeinated coffee group. After
adjusting for gestational age, pre-pregnancy BMI, parity
and smoking at entry to the study, the mean birth weight
for babies born to the caffeinated group was 16 g (95%
CI −40 to 73) lower than that of the decaffeinated
group. Although the difference was not significant,
when statistical uncertainty is considered, it is compatible
with our results of a 33 g lower birth weight (95% CI
4 to 63) for moderate caffeine intake (150 to 349 mg/day)
as compared with no or very low caffeine intake.
Our meta-analysis has several strengths. We searched
databases with no language restriction to increase the
completeness of studies identification. In addition, we
included only prospective studies and, thus, reduced the
influence of selection bias, recall bias and reverse caus-
ation in our results. Lastly, we not only compared the
highest category with the lowest categories but divided
maternal caffeine intake into four levels and also conduc-
ted a dose–response analysis.
However, our study also has several limitations that
have to be considered in the interpretation of our findings.
Measurement error in the assessment of caffeine intake
may have affected the results. The included studies relied
on questionnaires for caffeine assessment. However, in
most studies an interviewer-administered questionnaire
was used, which may have improved the completeness of
their data collection. Furthermore, validation studies have
shown that self-reports of major sources of caffeine such
as coffee and tea are, in general, reasonably accurate and
reliable [50,51]. Another potential limitation was that two
of the included studies (conducted in Italy and Denmark)
used coffee consumption as the proxy of total caffeine
intake. However, in these European populations coffee
consumption is high and in a similar Swedish study coffee
was the predominant source (accounting for 76%) of all
caffeine ingested by pregnant women [52]. In our stratified
analysis, the summary estimates did not differ substan-
tially by assessment of coffee versus total caffeine intake.
The caffeine assessments in the remaining studies were
reasonably comprehensive. Most studies considered at
least the intakes of coffee, tea and caffeinated-soft drinks
[6,9,23,24,30-35,44], while many also additionally considered
other sources such as cocoa products [6,9,23,30,31,33-35]
and caffeine-containing medication [6,23,30,34]. Consump-
tion of energy drinks containing a relatively high amount
of caffeine has been becoming more common, especially
since the mid-2000s [53,54]. However, most included stud-
ies in this meta-analysis were conducted before that period.
Furthermore, the contribution of energy drinks to total
caffeine intakes was found to be small in two recently
published studies included in this meta-analysis—1% of
caffeine intake in the CARE study and 7% (‘sugar sweet-
ened caffeinated-soft drinks including energy drinks’)i n
Sengpiel et al.’ss t u d y[ 6 , 9 ]a sw e l la so t h e rs t u d i e si n
pregnant women or women of child-bearing age [55,56].
Another issue is that three of the included studies had a
relatively high median caffeine level for reference category
[25,27,35], probably reflecting the high caffeine intake in
these populations. However, this should have resulted in
more conservative pooled effect estimates as it would re-
duce the contrast in caffeine intake between the compared
groups.
We combined low birth weight, SGA and IUGR in our
main analysis. Birth weight is influenced by both duration
Figure 4 Birth weight difference according to maternal caffeine
intake. Low caffeine intake: 50 to 149 mg/day; moderate caffeine
intake: 150 to 349 mg/day; high caffeine intake: ≥350 mg/day. Black
dots indicate study-specific effect estimates, sizes of the grey squares
correspond to the weights of the studies, horizontal lines indicate
95% CIs and diamonds indicate the summary estimates with their
corresponding 95% CIs. CI, confidence interval.
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weight can result from preterm delivery, insufficient fetal
growth or both, whereas SGA and IUGR only reflect fetal
growth. Nonetheless, in a recent meta-analysis by Maslova
et al. [4], the authors did not observe a substantial associ-
ation between maternal caffeine intake during pregnancy
and the risk of preterm birth. Hence, it seems likely that
the association between maternal caffeine intake and the
risk of low birth weight in our meta-analysis was due to
lower fetal growth rather than preterm delivery. Further-
more, in our stratified analysis the pooled effect estimates
for associations with caffeine intake were similar for studies
with low birth weight, SGA and IUGR as an outcome.
Residual confounding by unmeasured or imperfectly
measured covariates should also be considered as a poten-
tial limitation of our meta-analysis. A majority of the in-
cluded studies adjusted for potential confounders rather
comprehensively. We only included studies that consid-
ered potential confounding by smoking either by adjusting
for it in multivariable models or reporting that such
adjustment had minimal influence on the results. In
addition, most studies adjusted for gestational age, fetal
sex and maternal characteristics including age, weight and
height, parity, alcohol intake and socio-economic status.
Smoking tends to correlate with caffeine intake [9,23]
and is a known risk factor for low birth weight [57].
Smoking is, therefore, an important potential confounder
of the association between caffeine intake and low birth
weight. The seven included studies that reported results
for potential interaction between caffeine intake and smok-
ing in relation to low birth weight [9,23,27,28,30,31,35]
either did not suggest differences in association between
smokers and non-smokers [9,23,28,30,31] or suggested
a stronger association in non-smokers [27,35]. It is re-
assuring that associations between caffeine intake and
birth weight outcomes were observed in non-smokers,
because residual confounding by intensity of smoking is
not a concern in this group. However, in a study com-
paring self-reported smoking status and smoking status
defined by biomarker (serum cotinine level), the non-
disclosure rate of active smoking was higher among preg-
nant women (22.9%) than non-pregnant women (9.2%)
[58]. Using self-reported maternal smoking status to
adjust for confounding by smoking may, thus, lead to
residual confounding. Nonetheless, in the CARE study,
maternal caffeine intakes during all three trimesters
of pregnancy were associated with a higher risk of
fetal growth restriction even after adjustment for salivary
cotinine.
Pregnancy symptoms including nausea, vomiting and
aversions to smells and taste are more common in
healthy pregnancies. Women with healthy pregnancies
are more likely to decrease their caffeine consumption
in response to pregnancy symptoms [15] and there is a
suggestion that pregnancy symptoms can partly account
for the relationship of caffeine intake and adverse preg-
nancy outcomes, such as low birth weight. Nonetheless,
in a recent large cohort study by Sengpiel et al., the
observation that higher maternal caffeine intake was
associated with higher SGA risk was not affected by
adjustment for nausea [9]. Furthermore, in the CARE
study nausea and vomiting in pregnancy was not associ-
ated with fetal growth restriction and did not modify the
association between maternal caffeine intake and fetal
growth restriction [59].
Thus, the results of the original studies do not suggest
that confounding explains the association between caf-
feine intake and low birth weight. Nevertheless, residual
confounding cannot be completely ruled out in observa-
tional studies.
In addition to methodological limitations of the ori-
ginal studies, publication bias can affect the results of
meta-analyses. In our meta-analysis, statistical tests for
publication bias or the funnel plot did not suggest
publication bias, but this type of bias can never be
fully ruled out.
We assumed a linear relationship in our dose–response
analysis as there was no evidence of departure from linear-
ity. Also, our analysis based on categories of caffeine intake
suggested a graded association between caffeine intake and
the risk of low birth weight. We acknowledge that in the
conduct of a meta-analysis, the use of reported data for
categories of intake instead of individual level data may
have reduced our power to detect a non-linear association.
However, our finding that there appears to be no clear
threshold level of intake below which caffeine does not
affect birth weight is in concordance with two original
studies that examined dose–response relationships using
sextiles [9] or spline regression analysis [6]. Both of these
studies suggested a monotonic association between caf-
feine intake and risk of low birth weight with risk being
elevated even for low intakes as compared with caffeine
abstinence.
The exact mechanism through which caffeine may im-
pair fetal growth remains unsettled. One of the hypothe-
sized mechanisms is that caffeine increases the release of
catecholamines, which may lead to vasoconstriction in
the uteroplacental circulation and fetal hypoxia and
eventually affect fetal growth and development [12,13].
Indeed, a 25% reduction in intervillous placental blood
flow after maternal ingestion of just 200 mg of caffeine
has been documented [6,13]. Another hypothesis is that
caffeine increases the cellular concentration of cyclic
AMP by inhibiting phosphodiesterase, an enzyme respon-
sible for the breakdown of cyclic AMP [9,60]. A built-
up of cyclic AMP may influence cell division or lead to
catecholamine-mediated vasoconstriction, thus affecting
fetal growth [31,61].
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This systematic review and meta-analysis supports the
hypothesis that higher maternal caffeine intake during
pregnancy is associated with a higher risk of delivering
low birth weight infants. In our meta-analysis based on
categories of caffeine consumption, the risk for low birth
weight increased with increasing levels of caffeine intake.
The risk for low birth weight was significantly higher
even in the low (50 to 149 mg/day) and moderate (150
to 349 mg/day) caffeine intake groups, as compared with
the reference group with no or very low caffeine intake.
Our dose–response analysis also suggested a linear asso-
ciation with low birth weight across the range of caffeine
intakes. This seems relevant for public health recom-
mendations as it indicates that the risk of low birth
weight may be elevated even for caffeine intakes below
the recommended maximum limit of the current guide-
lines for pregnant women (300 mg/day by the World
Health Organization and 200 mg/day by the Nordic
Nutrition Recommendations and the American College
of Obstetricians and Gynecologists [9,62]). Nonetheless,
although our meta-analysis summarizes the best evi-
dence available to date, we cannot exclude the possibility
that potential biases, such as reverse causation and re-
sidual confounding by smoking or pregnancy symptoms,
affected the observed association between caffeine intake
and risk of low birth weight. Results from previous studies
have highlighted the adverse impact of smoking and alco-
hol use during pregnancy on birth weight and other birth
outcomes [63-65]. Although abstaining from smoking and
alcohol consumption should be the mainstay of recom-
mendations to lower risk of low birth weight, reducing
caffeine intake during pregnancy may represent an add-
itional strategy to optimize fetal growth. In conclusion,
while a confirmation in large randomized controlled trials
would be desirable, our results do provide further support
for recommendations to limit caffeine intake during preg-
nancy to low levels.
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